Colorectal CancerFDA Approvals, News & UpdatesNewsworthy

Opdivo Approved for dMMR and MSI-H Metastatic Colorectal Cancer

December 2017 Vol 3 No 6

On July 31, 2017, the FDA approved a new use for Opdivo (nivolumab; from Bristol-Myers Squibb) for adults with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer that progressed after treatment with a chemotherapy regimen.

The approval of this new indication was based on a clinical trial showing that 28% of adult patients responded to treatment with Opdivo, including 1 complete response (no sign of disease) and 14 partial responses. In 67% of patients, the responses lasted 6 months or longer. Among the 74 patients in the overall population, there was an objective response rate of 32%.

Opdivo was previously approved by the FDA for many types of cancer, including melanoma, lung cancer, kidney cancer, head and neck cancer, liver cancer, lymphoma, and bladder cancer.

Recommended For You
CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
On April 17, 2020, the FDA approved Pemazyre (pemigatinib; from Incyte)—an oral inhibitor of FGFR gene fusions or rearrangements 1, 2, and 3— for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma and the biomarker FGFR2 gene fusions.
Breast CancerFDA Approvals, News & Updates
Approved for Breast Cancer and HER2 Biomarker
On April 17, 2020, the FDA approved Tukysa (tucatinib; from Seattle Genetics), a kinase inhibitor, for use with chemotherapy (trastuzumab and capecitabine) for the treatment of adults with unresectable (cannot be removed by surgery) advanced or metastatic (spreading) HER2-positive breast cancer, after 1 or more previous treatments. Tukysa blocks the kinase enzyme, thereby blocking the growth of cancer cells.
Bladder CancerFDA Approvals, News & UpdatesUrothelial Cancer
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
In April 2020, the FDA approved Jelmyto as the first treatment for low-grade upper-tract urothelial cancer, a rare cancer that affects the urinary system.
COVID-19 (Coronavirus)From Your NavigatorNewsworthyWeb Exclusives
Coronavirus FAQs for People with Cancer: Interview with Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
By Yvette Florio Lane
COVID-19, the respiratory infection caused by the new coronavirus, is making headlines around the world. Find out what you need to know about this global disease outbreak and how to protect yourself.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.